SK Chemicals Co., Ltd.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
As of 2026-10-10, SK Chemicals Co., Ltd. has 149 Korean MFDS drug approvals, 68 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2017 and listed on KOSPI in 2018, SK Chemicals operates both chemical materials and pharmaceutical/bio businesses. Its Green Chemicals Biz. produces eco-friendly Copolyester resins (SKYGREEN, ECOZEN, ECOTRIA) and bio-polyol (PO3G), while its Pharma segment sells Joins, Ginexin, and rivastigmine patches, and its subsidiary SK Bioscience runs vaccine, IV solution, and CDMO businesses. In 2025, consolidated revenue was KRW 2,365.2 billion, with segment shares of 65.6% for Green Chemicals Biz., 20.6% for the Pharma segment, and 27.6% for SK Bioscience, while exports accounted for 50.3% of revenue versus 49.7% domestic.
Products & technology
- JoinsOsteoarthritis treatment (natural-derived drug)
- GinexinBlood circulation improvement agent
- Rivastigmine patchSynthetic pharmaceutical
- SKYGREEN Copolyester resinCosmetic containers, electronic parts, construction materials
- ECOZEN bio-based Copolyester resinElectronics, food containers, baby products
- ECOTRIA recycled Copolyester resinCosmetic containers, packaging, household goods
- Bio-polyol (PO3G)Bio-based material
Regulatory approvals
data.go.kr149 Korean MFDS drug approvals · 1981–2026
- MFDS drugVonosky Tab. 10mg (vonoprazan)2026-08-24Drug · Prescription · Approval202602455
- MFDS drugVonosky Tab. 20mg (vonoprazan)2026-08-24Drug · Prescription · Approval202602456
- MFDS drugSKYoneCAB Tablet 50mg(Tegoprazan)2026-08-11Drug · Prescription · Approval202602331
- MFDS drugSKYoneCAB Tablet 25mg(Tegoprazan)2026-08-11Drug · Prescription · Approval202602332
- MFDS drugEasyprafen Cap.2026-05-28Drug · Prescription · Approval202601558
- MFDS drugCool night tab.2026-05-20Drug · OTC · Notification202601464
- MFDS drugOmed Plus Tab. 10/300mg2026-05-13Drug · Prescription · Approval202601398
- MFDS drugOmed Plus Tab. 20/600mg2026-05-13Drug · Prescription · Approval202601399
- MFDS drugSilkyrea Cream(Urea)2026-04-07Drug · OTC · Notification202600967
- MFDS drugScar Reborn Gel2026-01-28Drug · OTC · Notification202600242
- MFDS drugTelamchlowTablet20/2.5/6.25mg2026-01-15Drug · Prescription · Approval202600129
- MFDS drugNose-Bell Tab.2025-11-03Drug · OTC · Notification202502838
Show 68 more
- MFDS drugTrast coin plaster2025-09-04Drug · OTC · Notification202502322
- MFDS drugLacto Q Tab.2025-09-01Drug · OTC · Notification202502290
- MFDS drugTrast Rubi Plaster2025-08-29Drug · OTC · Notification202502277
- MFDS drugMeco Mag Plus Tab.2025-08-28Drug · OTC · Notification202502267
- MFDS drugSokpyunhan Tab.2025-07-24Drug · OTC · Notification202501892
- MFDS drugLidoprone Cream2025-07-14Drug · OTC · Notification202501780
- MFDS drugCetirien Tab.2025-05-13Drug · OTC · Notification202501164
- MFDS drugjangencle capsule2025-05-01Drug · OTC · Notification202501091
- MFDS drugInvela Powder 0.8g(Sevelamer carbonate), Invela Powder 2.4g(Sevelamer carbonate),2025-04-15Drug · Prescription · Approval202500905
- MFDS drugCocoN Cap.2025-04-11Drug · OTC · Notification202500864
- MFDS drugGinexin Memocare Capsule2024-11-13Drug · OTC · Notification202402687
- MFDS drugTryp-S Tab.2024-06-25Drug · OTC · Notification202401527
- MFDS drugChondro-S 800 Tab.2024-06-20Drug · OTC · Notification202401489
- MFDS drugDam en Cool Tab.2024-04-05Drug · OTC · Notification202400780
- MFDS drugJoins-F Tab.2023-12-21Drug · Prescription · Approval202303397
- MFDS drugToszet A Tablet 10/10/10mg(Ezetimibe, Atorvastatin Calcium Trihydrate, Amlodipine Besylate)2023-11-06Drug · Prescription · Approval202303069
- MFDS drugToszet A Tablet 10/10/5mg(Ezetimibe, Atorvastatin Calcium Trihydrate, Amlodipine Besylate)2023-10-25Drug · Prescription · Approval202302979
- MFDS drugSuvexx Tablet2023-08-01Drug · Prescription · Approval202302313
- MFDS drugPower Join-S 600 Tab.2023-06-07Drug · OTC · Notification202301762
- MFDS drugToszet A Tablet 10/40/10mg(Ezetimibe, Atorvastatin Calcium Trihydrate, Amlodipine Besylate)2023-05-31Drug · Prescription · Approval202301714
- MFDS drugToszet A Tablet 10/20/10mg(Ezetimibe, Atorvastatin Calcium Trihydrate, Amlodipine Besylate)2023-05-31Drug · Prescription · Approval202301715
- MFDS drugToszet A Tablet 10/20/5mg(Ezetimibe, Atorvastatin Calcium Trihydrate, Amlodipine Besylate)2023-05-31Drug · Prescription · Approval202301716
- MFDS drugI-High Chewable Tab.Revoked2023-04-26Drug · OTC · Notification202301364
- MFDS drugTeglutik oral suspension2022-05-31Drug · Prescription · Approval202202295
- MFDS drugTrast Ibu Plaster(Ibuprofen)2022-03-29Drug · OTC · Notification202201233
- MFDS drugRemitch OD Tablet 2.5μg(Nalfurafine HCl)2021-10-26Drug · Prescription · Approval202107133
- MFDS drugCosca Tablet 25mg(Losartan Potassium)2021-04-13Drug · Prescription · Approval202103090
- MFDS drugToszet Tablet 10/20mg2021-01-08Drug · Prescription · Approval202100237
- MFDS drugToszet Tablet 10/10mg2021-01-08Drug · Prescription · Approval202100238
- MFDS drugToszet Tablet 10/40mg2021-01-08Drug · Prescription · Approval202100239
- MFDS drugGinexin-F Tablet 240mg(Ginkgo leaf dry extract)2020-12-24Drug · OTC · Approval202009212
- MFDS drugTrast Plaster(Piroxicam)2020-12-01Drug · OTC · Notification202008405
- MFDS drugLaton PR Tablet 2mg(Melatonin)2020-09-22Drug · Prescription · Approval202006549
- MFDS drugTocinib Tablet 5mg(Tofacitinib)2020-09-07Drug · Prescription · Approval202006210
- MFDS drugTrast Felbin Plaster(Felbinac)Revoked2020-07-07Drug · OTC · Notification202004913
- MFDS drugTrast Finger Plaster(Ketoprofen)2020-04-22Drug · OTC · Notification202002866
- MFDS drugTrast Difen Plaster(Diclofenac)2020-04-21Drug · OTC · Notification202002817
- MFDS drugRenexin CR Tablet2020-03-24Drug · Prescription · Approval202002062
- MFDS drugOngentys Capsule 50mg(Opicapone)2019-11-26Drug · Prescription · Approval201908093
- MFDS drugOngentys Capsule 25mg(Opicapone)2019-11-26Drug · Prescription · Approval201908094
- MFDS drugNewdotop Cataplasma(Lidocaine)2019-11-18Drug · Prescription · Notification201907969
- MFDS drugRomelain Enteric Coated Tablet (Bromelain)2019-11-12Drug · OTC · Notification201907883
- MFDS drugVimsk Injection(Lacosamide)2019-03-29Drug · Prescription · Approval201901941
- MFDS drugSumediphen 8 hours ER Tablet 650mg(Acetaminophen)Revoked2018-12-24Drug · OTC · Approval201805241
- MFDS drugGinexin-F Tablet 120mg(Ginkgo leaf dry extract)2018-10-30Drug · OTC · Notification201804292
- MFDS drugCosca EX Tablet 10/50mg2018-06-12Drug · Prescription · Approval201802434
- MFDS drugCosca EX Tablet 5/100mg2018-06-12Drug · Prescription · Approval201802435
- MFDS drugCosca EX Tablet 5/50mg2018-06-12Drug · Prescription · Approval201802436
- MFDS drugCaremixin Plus Ointment2018-05-11Drug · OTC · Notification201802006
- MFDS drugSrtec Soft Capsule 10mg(Cetirizine HCl)Revoked2018-01-09Drug · OTC · Notification201800131
- MFDS drugQudexy XR Capsule 100mg(Topiramate)2017-08-08Drug · Prescription · Approval201706471
- MFDS drugQudexy XR Capsule 200mg(Topiramate)2017-08-08Drug · Prescription · Approval201706472
- MFDS drugQudexy XR Capsule 25mg(Topiramate)2017-08-08Drug · Prescription · Approval201706473
- MFDS drugQudexy XR Capsule 50mg(Topiramate)2017-08-08Drug · Prescription · Approval201706474
- MFDS drugDoublezyme Tablet2016-10-13Drug · OTC · Notification201606067
- MFDS drugVimsk Tablet 150mg(Lacosamide)2016-08-31Drug · Prescription · Approval201605341
- MFDS drugVimsk Tablet 200mg(Lacosamide)2016-08-31Drug · Prescription · Approval201605342
- MFDS drugVimsk Tablet 50mg(Lacosamide)2016-08-31Drug · Prescription · Approval201605343
- MFDS drugVimsk Tablet 100mg(Lacosamide)2016-08-31Drug · Prescription · Approval201605344
- MFDS drugSK Rivaroxaban Tablet 2.5mgRevoked2016-07-06Drug · Prescription · Approval201604177
- MFDS drugSkad B Tablet(Amlodopine Besylate)2016-06-10Drug · Prescription · Approval201603342
- MFDS drugNebido, Solution for injection 250 mg per 1ml2015-12-17Drug · Prescription · Approval201508309
- MFDS drugExonin CR Tablet(Eperisone HCl)2015-03-31Drug · Prescription · Approval201501694
- MFDS drugInvela Tablet(Sevelamer carbonate)2015-03-31Drug · Prescription · Approval201501773
- MFDS drugAnpla X SR Tablet 300mg(Sarpogrelate HCl)2015-01-23Drug · Prescription · Approval201500371
- MFDS drugNapmed Tablet 500/20mg2014-07-10Drug · Prescription · Approval201403085
- MFDS drugWondron Patch 10(Rivastigmine)2014-03-31Drug · Prescription · Approval201401524
- MFDS drugWondron Patch 5(Rivastigmine)2014-03-31Drug · Prescription · Approval201401525
Showing the 80 most recent of 149 records.
Clinical trials
data.go.kr60 MFDS clinical trial authorisations · 2012–2026 (Phase 1 20 · Phase 3 19 · Bioequivalence 15 · Phase 2 4 · Phase 1/2 2)
- Phase 1AD-2312026-05-08
1 trial site
- Phase 1SID25012025-12-03
2 trial sites
- Phase 1SID24052025-10-28
1 trial site
- Phase 3SID24062025-05-30
1 trial site
- Phase 1AD-1202025-03-17
2 trial sites
- BioequivalenceMSF1002024-08-08
1 trial site
- BioequivalenceSID21022024-06-12
2 trial sites
- BioequivalenceSID21022023-10-26
2 trial sites
- BioequivalenceSID21012023-05-22
1 trial site
- Phase 3SKO_22012022-11-24
1 trial site
- Phase 1SID19032022-06-02
2 trial sites
- Phase 1SID19032021-09-29
2 trial sites
Show 48 more
- BioequivalenceSID19012021-06-09
2 trial sites
- Phase 3SKCPT2020-11-30
14 trial sites
- Phase 1QDX2020-05-08
1 trial site
- Bioequivalence코스카정100밀리그램(로사르탄칼륨)2016-08-31
2 trial sites
- Phase 3SID1422016-08-05
19 trial sites
- Phase 1SID1422016-05-16
1 trial site
- Phase 3SK-NBP6082016-03-07
15 trial sites
- Phase 3SK-NBP6082016-03-07
1 trial site
- Phase 1NBP621/6192016-02-12
1 trial site
- Phase 1/2SK-NBP613경구용약독화로타생바이러스백신(사람-소재배열)2015-11-18
5 trial sites
- Bioequivalence미가드정2.5mg(프로바트립탄숙신산염일수화물)2015-08-18
2 trial sites
- Phase 3SK-NBP6082015-07-30
8 trial sites
- Phase 1SID1422015-06-04
1 trial site
- Bioequivalence에스케이리바록사반정2.5밀리그램(리바록사반)2015-01-08
2 trial sites
- Bioequivalence에스케이리바록사반정20밀리그램(리바록사반)2015-01-05
2 trial sites
- BioequivalenceSID1252014-11-17
2 trial sites
- Phase 3THVD-2012014-11-10
16 trial sites
- Phase 3SK-NBP607QIV세포배양인플루엔자백신주-4가2014-09-29
8 trial sites
- Phase 3SK-NBP607QIV세포배양인플루엔자백신주-4가2014-09-29
10 trial sites
- Phase 3CPT302014-08-07
13 trial sites
- Phase 1SID1232014-08-06
1 trial site
- Phase 2SID1232014-05-20
10 trial sites
- Phase 3폐렴구균-단백접합백신주(NBP606)(정제폐렴구균다당류-디프테리아CRM197단백질접합체) 13가2014-05-16
13 trial sites
- Phase 1SK-NBP613경구용약독화로타생바이러스백신(사람-소재배열)2014-03-21
1 trial site
- Phase 1SK-NBP615인유두종바이러스백신주-4가2014-03-07
1 trial site
- Phase 1/2SK-NBP607QIV세포배양인플루엔자백신주-4가2014-02-06
1 trial site
- Phase 1SKI26702014-02-05
6 trial sites
- Phase 1CPT302013-12-24
1 trial site
- Phase 3폐렴구균-단백접합백신주(NBP606)(정제폐렴구균다당류-디프테리아CRM197단백질접합체) 13가2013-11-21
15 trial sites
- Phase 3SK-NBP6082013-11-07
6 trial sites
- Phase 3폐렴구균-단백접합백신주(NBP606)(정제폐렴구균다당류-디프테리아CRM197단백질접합체) 13가2013-11-05
12 trial sites
- Bioequivalence에스케이코스카플러스에프정2013-10-14
2 trial sites
- Phase 2YKP108112013-10-01
19 trial sites
- Phase 2CPT302013-09-26
6 trial sites
- Bioequivalence에스케이리바스티그민패취15(리바스티그민)2013-09-02
2 trial sites
- Phase 1SID1232013-09-02
1 trial site
- Phase 3세포배양인플루엔자백신주2013-08-23
10 trial sites
- Phase 3세포배양인플루엔자백신주2013-08-23
7 trial sites
- Bioequivalence엠빅스에스구강붕해필름50밀리그램(미로데나필)2013-08-12
1 trial site
- Phase 1CPT302013-04-23
1 trial site
- Bioequivalence에스케이리바스티그민패취10(리바스티그민)2013-02-01
2 trial sites
- Phase 3폐렴구균-단백접합백신주(NBP606)(정제폐렴구균다당류-디프테리아CRM197단백질접합체) 13가2012-10-25
15 trial sites
- Phase 1SK-NBP6082012-09-03
1 trial site
- Phase 1세포배양인플루엔자백신주2012-07-31
10 trial sites
- Phase 3SOTB072012-07-09
22 trial sites
- Phase 2SKI32462012-07-09
17 trial sites
- Bioequivalence프로맥정75밀리그램(폴라프레징크)2012-06-18
- Phase 1페브릭정40mg(페북소스타트) (TMX-67)2012-01-02
1 trial site
Global clinical trials
ClinicalTrials.gov · sponsor-matchedPhase 4 · Completed · 2022-12 · NCT05445895
Phase 4 · Unknown · 2022-09 · NCT05400395
Phase 1 · Completed · 2022-06 · NCT05453786
Phase 1 · Completed · 2021-11 · NCT05236998
Phase 4 · Completed · 2021-07 · NCT05906199
Phase 4 · Completed · 2021-06 · NCT04821687
Phase 3 · Completed · 2021-01 · NCT05930080
Phase 1 · Completed · 2020-07 · NCT04401137
Phase 3 · Completed · 2017-02 · NCT03318276
Phase 3 · Completed · 2016-10 · NCT03020628
Show 43 more trials
Phase 2 · Completed · 2016-05 · NCT03114982
Phase 3 · Completed · 2015-11 · NCT02927444
Phase 3 · Completed · 2015-09 · NCT03120364
Phase 1 · Completed · 2015-06 · NCT02625714
Phase 3 · Completed · 2015-01 · NCT02485067
Phase 1 · Completed · 2014-11 · NCT02485041
Phase 3 · Completed · 2014-10 · NCT02467842
Phase 3 · Completed · 2014-09 · NCT02201030
Phase 3 · Completed · 2014-09 · NCT02621164
Phase 1 · Completed · 2014-06 · NCT02202408
Phase 1/2 · Completed · 2014-02 · NCT03826719
Phase 2/3 · Completed · 2014-01 · NCT03116594
Phase 2 · Completed · 2013-12 · NCT02082457
Phase 3 · Completed · 2013-12 · NCT02079207
Phase 3 · Completed · 2013-11 · NCT02621177
Phase 1 · Completed · 2013-10 · NCT02485028
Phase 3 · Completed · 2013-09 · NCT02344134
Phase 3 · Terminated · 2013-01 · NCT01907763
Phase 2 · Completed · 2013-01 · NCT02079675
Phase 1 · Completed · 2012-11 · NCT03121638
Phase 1 · Completed · 2012-09 · NCT03893669
Phase 1 · Completed · 2012-01 · NCT01563432
Phase 2 · Completed · 2011-08 · NCT01578811
Phase 3 · Completed · 2010-10 · NCT01513850
Phase 4 · Completed · 2010-08 · NCT01293955
Phase 3 · Completed · 2010-05 · NCT01249196
Phase 3 · Completed · 2009-10 · NCT00931008
Phase 2 · Completed · 2009-07 · NCT00936624
Phase 1 · Completed · 2008-12 · NCT01248650
Phase 1 · Completed · 2008-10 · NCT00846274
Phase 1 · Completed · 2008-05 · NCT00626743
Phase 3 · Completed · 2008-04 · NCT01513161
Phase 3 · Completed · 2007-12 · NCT00644007
Phase 3 · Completed · 2007-11 · NCT00705861
Phase 1 · Completed · 2007-05 · NCT00689858
Phase 2 · Completed · 2007-04 · NCT00443417
- Phase I Study to Investigate the Drug Interaction After Oral Administration of Tamsulosin and SK3530
Phase 1 · Completed · 2007-04 · NCT00489606
Phase 1 · Completed · 2007-03 · NCT00489450
Phase 1 · Completed · 2006-12 · NCT00443625
Phase 3 · Completed · 2006-11 · NCT00821483
Phase 3 · Completed · 2006-08 · NCT00821392
Phase 3 · Completed · 2006-01 · NCT00289406
Phase 2 · Terminated · 2004-09 · NCT00351065
Key disclosures
KRX KIND via OpenDARTPublications
PubMed · affiliation-matched- A novel PAAoptosis-inducing ERRα-targeting compound for combating hematopoietic and solid cancers.
Cell death discovery · 2026-03 · Seo W, Heo Y, Tran KV 외 15
- Enhancing Lithium-Ion Diffusion Kinetics in a 3D Lithium Metal Host through Surface Modification with Hierarchical Multimetal Oxides.
ACS applied materials & interfaces · 2024-06 · Jung D, Cho Y, Kim D 외 4
- Effects of SKCPT on Osteoarthritis in Beagle Meniscectomy and Cranial Cruciate Ligament Transection Models.
International journal of molecular sciences · 2023-10 · Kim HM, Kang M, Jung YS 외 5
- Chemical Constituents from the Roots and Rhizomes of Sophora tonkinensis and Their Effects on Proprotein Convertase Substilisin/Kexin Type 9 Expression.
ACS omega · 2022-06 · Pel P, Chae HS, Nhoek P 외 7
- Surface Modification of Sulfur-Assisted Reduced Graphene Oxide with Poly(phenylene sulfide) for Multifunctional Nanocomposites.
Polymers · 2022-02 · Choi M, Kim J, Oh Y 외 6
- First-in-Human, Double-Blind, Randomized Controlled Trial of an Oral Dose of GnRH Antagonist TU2670 in Healthy Women.
The Journal of clinical endocrinology and metabolism · 2021-03 · Han S, Cho YS, Yoon SK 외 13
- Lack of Correlation between In Vitro and In Vivo Studies on the Inhibitory Effects of (‒)-Sophoranone on CYP2C9 is Attributable to Low Oral Absorption and Extensive Plasma Protein Binding of (‒)-Sophoranone.
Pharmaceutics · 2020-04 · Zheng YF, Bae SH, Huang Z 외 7
- Reply by Authors.
The Journal of urology · 2019-09 · Ko KJ, Kim KH, Kim SW 외 9
- Efficacy and Safety of Tolterodine and Pilocarpine in Patients with Overactive Bladder.
The Journal of urology · 2019-09 · Ko KJ, Kim KH, Kim SW 외 9
- Prenylated Flavonoids from the Roots and Rhizomes of Sophora tonkinensis and Their Effects on the Expression of Inflammatory Mediators and Proprotein Convertase Subtilisin/Kexin Type 9.
Journal of natural products · 2019-02 · Ahn J, Kim YM, Chae HS 외 6
Show 58 more publications
- Vaccines, inspiring innovation in health.
Vaccine · 2018-11 · Pagliusi S, Dennehy M, Kim H
- Development of a diagnostic system for detection of specific antibodies and antigens against Middle East respiratory syndrome coronavirus.
Microbiology and immunology · 2018-09 · Lee K, Ko HL, Lee EY 외 10
- A Randomized, Double-blind, Active-controlled Clinical Trial of a Cell Culture-derived Inactivated Trivalent Influenza Vaccine (NBP607) in Healthy Children 6 Months Through 18 Years of Age.
The Pediatric infectious disease journal · 2018-06 · Oh CE, Choi UY, Eun BW 외 9
- Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children.
Vaccine · 2018-06 · Capeding MR, Teshome S, Saluja T 외 19
- Double-Injected Human Stem Cells Enhance Rehabilitation in TBI Mice Via Modulation of Survival and Inflammation.
Molecular neurobiology · 2018-06 · Kim C, Park JM, Kong T 외 5
- Creation, characterization, and assignment of opsonic values for a new pneumococcal OPA calibration serum panel (Ewha QC sera panel A) for 13 serotypes.
Medicine · 2018-04 · Burton RL, Kim HW, Lee S 외 9
- Synthesis and biological evaluation of 3-(2-aminoethyl) uracil derivatives as gonadotropin-releasing hormone (GnRH) receptor antagonists.
European journal of medicinal chemistry · 2018-02 · Kim SM, Lee M, Lee SY 외 6
- Overexpression of histone methyltransferase NSD in Drosophila induces apoptotic cell death via the Jun-N-terminal kinase pathway.
Biochemical and biophysical research communications · 2018-02 · Jeong Y, Kim T, Kim S 외 3
- Comparison of pharmacokinetics and safety of fixed-dose combination of SKI306X and aceclofenac versus separate tablets in healthy subjects.
Translational and clinical pharmacology · 2017-12 · Meng X, Oh ES, Park MS 외 3
- Enhanced methane production and wastewater sludge stabilization of a continuous full scale thermal pretreatment and thermophilic anaerobic digestion.
Bioresource technology · 2017-12 · Han D, Lee CY, Chang SW 외 1
- SKI3301, a purified herbal extract from Sophora tonkinensis, inhibited airway inflammation and bronchospasm in allergic asthma animal models in vivo.
Journal of ethnopharmacology · 2017-07 · Yoo H, Kang M, Pyo S 외 4
- Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects.
Human vaccines & immunotherapeutics · 2017-07 · Choi WS, Noh JY, Song JY 외 12
- Comparative evaluation of a newly developed 13-valent pneumococcal conjugate vaccine in a mouse model.
Human vaccines & immunotherapeutics · 2017-05 · Park C, Kwon EY, Choi SM 외 7
- Discovery of 2-((R)-4-(2-Fluoro-4-(methylsulfonyl)phenyl)-2-methylpiperazin-1-yl)-N-((1R,2s,3S,5S,7S)-5-hydroxyadamantan-2-yl)pyrimidine-4-carboxamide (SKI2852): A Highly Potent, Selective, and Orally Bioavailable Inhibitor of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1).
Journal of medicinal chemistry · 2016-11 · Ryu JH, Lee JA, Kim S 외 10
- Impact of Long-Term Proton Pump Inhibitor Therapy on Gut Microbiota in F344 Rats: Pilot Study.
Gut and liver · 2016-11 · Shin CM, Kim N, Kim YS 외 9
- Discovery of an Orally Bioavailable Gonadotropin-Releasing Hormone Receptor Antagonist.
Journal of medicinal chemistry · 2016-10 · Kim SM, Lee M, Lee SY 외 9
- Correction: Chae, H.S., et al. Anti-Inflammatory Effects of 6,8-Diprenyl-7,4'-dihydroxyflavanone from Sophora tonkinensis on Lipopolysaccharide-Stimulated RAW 264.7 Cells. Molecules. 2016, 21, 1049.
Molecules (Basel, Switzerland) · 2016-10 · Chae HS, Yoo H, Kim YM 외 3
- Anti-Inflammatory Effects of 6,8-Diprenyl-7,4'-dihydroxyflavanone from Sophora tonkinensis on Lipopolysaccharide-Stimulated RAW 264.7 Cells.
Molecules (Basel, Switzerland) · 2016-08 · Chae HS, Yoo H, Kim YM 외 3
- A potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, SKI2852, ameliorates metabolic syndrome in diabetic mice models.
European journal of pharmacology · 2015-12 · Oh H, Jeong KH, Han HY 외 8
- Immunogenicity and safety of a cell culture-derived inactivated trivalent influenza vaccine (NBP607): A randomized, double-blind, multi-center, phase 3 clinical trial.
Vaccine · 2015-10 · Song JY, Cheong HJ, Lee J 외 9
- Effect of SKI2670, a novel, orally active, non-peptide GnRH antagonist, on hypothalamic-pituitary-gonadal axis.
Life sciences · 2015-10 · Kim SM, Yoo T, Lee SY 외 8
- Synthesis and optimization of picolinamide derivatives as a novel class of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors.
Bioorganic & medicinal chemistry letters · 2015-04 · Ryu JH, Kim S, Lee JA 외 6
- SKI2162, an inhibitor of the TGF-β type I receptor (ALK5), inhibits radiation-induced fibrosis in mice.
Oncotarget · 2015-02 · Park JH, Ryu SH, Choi EK 외 4
- Synthesis and biological evaluation of picolinamides as potent inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1).
Bioorganic & medicinal chemistry letters · 2015-02 · Ryu JH, Kim S, Han HY 외 5
- Pharmacokinetic properties of trifolirhizin, (-)-maackiain, (-)-sophoranone and 2-(2,4-dihydroxyphenyl)-5,6-methylenedioxybenzofuran after intravenous and oral administration of Sophora tonkinensis extract in rats.
Xenobiotica; the fate of foreign compounds in biological systems · 2015-01 · Jang SM, Bae SH, Choi WK 외 7
- Inhibitory effects of SKI3246, the rhizome extract of Atractylodes japonica, on visceral hypersensitivity in experimental irritable bowel syndrome rat models.
Archives of pharmacal research · 2015-01 · Son HJ, Jung K, Park YH 외 7
- Flavonoids and arylbenzofurans from the rhizomes and roots of Sophora tonkinensis with IL-6 production inhibitory activity.
Bioorganic & medicinal chemistry letters · 2014-12 · Yoo H, Chae HS, Kim YM 외 6
- SKI306X inhibition of glycosaminoglycan degradation in human cartilage involves down-regulation of cytokine-induced catabolic genes.
The Korean journal of internal medicine · 2014-09 · Choi CH, Kim TH, Sung YK 외 4
- Gastroprotective effect of Cochinchina momordica seed extract in nonsteroidal anti-inflammatory drug-induced acute gastric damage in a rat model.
Gut and liver · 2014-01 · Lim JH, Kim JH, Kim N 외 9
- Prophylactic and therapeutic vaccines for obesity.
Clinical and experimental vaccine research · 2014-01 · Na HN, Kim H, Nam JH
- Generation and Characterization of Recombinant Influenza A(H1N1) Viruses Resistant to Neuraminidase Inhibitors.
Osong public health and research perspectives · 2013-12 · Choi W, Shin JY, Jeong HE 외 4
- Determination of dapoxetine in rat plasma by ultra-performance liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2013-05 · Kim TK, Kim IS, Hong SH 외 3
- Effects of structural difference of ionic liquids on the catalysis of horseradish peroxidase.
Journal of microbiology and biotechnology · 2009-07 · Hong ES, Park JH, Yoo IK 외 1
- Ginkgo biloba extract enhances antiplatelet and antithrombotic effects of cilostazol without prolongation of bleeding time.
Thrombosis research · 2009-07 · Ryu KH, Han HY, Lee SY 외 6
- SK-PC-B70M from Pulsatilla koreana improves scopolamine-induced impairments of memory consolidation and spatial working memory.
Brain research · 2007-12 · Han CK, Park YH, Jin DQ 외 3
- Development of LC/MS/MS assay for the determination of 5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-7-propyl-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one (SK3530) in human plasma: application to a clinical pharmacokinetic study.
Journal of pharmaceutical and biomedical analysis · 2007-09 · Shin BS, Hu SK, Kim J 외 7
- Cognition-enhancing and neuroprotective effects of hederacolchiside-E from Pulsatilla koreana.
Planta medica · 2007-06 · Han CK, Choi WR, Oh KB
- Effects of SKI306X on arachidonate metabolism and other inflammatory mediators.
Biological & pharmaceutical bulletin · 2005-09 · Kim JH, Ryu KH, Jung KW 외 3
- SKI306X suppresses cartilage destruction and inhibits the production of matrix metalloproteinase in rabbit joint cartilage explant culture.
Journal of pharmacological sciences · 2005-07 · Kim JH, Ryu KH, Jung KW 외 3
- SKI306X, an oriental herbal mixture, suppresses gastric leukotriene B4 synthesis without causing mucosal injury and the diclofenac-induced gastric lesions.
Life sciences · 2005-07 · Kim JH, Rhee HI, Jung IH 외 6
- Effects of gentianine on the production of pro-inflammatory cytokines in male Sprague-Dawley rats treated with lipopolysaccharide (LPS).
Biological & pharmaceutical bulletin · 2005-04 · Kwak WJ, Kim JH, Ryu KH 외 3
- Papyriflavonol A from Broussonetia papyrifera inhibits the passive cutaneous anaphylaxis reaction and has a secretory phospholipase A2-inhibitory activity.
Biological & pharmaceutical bulletin · 2003-03 · Kwak WJ, Moon TC, Lin CX 외 10
- Loniceroside C, an antiinflammatory saponin from Lonicera japonica.
Chemical & pharmaceutical bulletin · 2003-03 · Kwak WJ, Han CK, Chang HW 외 3
- Involvement of oxidative stress in the regulation of H(2)S production during ultradian metabolic oscillation of Saccharomyces cerevisiae.
FEMS microbiology letters · 2003-02 · Kwak WJ, Kwon GS, Jin I 외 2
- Recent advances in topoisomerase I-targeting agents, camptothecin analogues.
Mini reviews in medicinal chemistry · 2002-12 · Kim DK, Lee N
- Effects of Ginkgetin from Ginkgo biloba Leaves on cyclooxygenases and in vivo skin inflammation.
Planta medica · 2002-04 · Kwak WJ, Han CK, Son KH 외 4
- Synthesis and phosphodiesterase inhibitory activity of new sildenafil analogues containing a carboxylic acid group in the 5'-sulfonamide moiety of a phenyl ring.
Bioorganic & medicinal chemistry · 2001-11 · Kim DK, Lee JY, Lee N 외 9
- Pharmacokinetic studies of 2-amino-9-(3-acetoxymethyl-4-isopropoxycarbonyl-oxybut-1-yl)purine, an oral prodrug for the antiviral agent penciclovir.
Drug metabolism and disposition: the biological fate of chemicals · 2001-07 · Choi WS, Im GJ, Kim DK 외 8
- Synthesis and phosphodiesterase 5 inhibitory activity of new 5-phenyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one derivatives containing an N-acylamido group phenyl ring.
Bioorganic & medicinal chemistry · 2001-07 · Kim DK, Ryu DH, Lee N 외 9
- Synthesis and phosphodiesterase 5 inhibitory activity of novel phenyl ring modified sildenafil analogues.
Bioorganic & medicinal chemistry · 2001-06 · Kim DK, Lee N, Lee JY 외 12
- Synthesis and biological evaluation of novel A-ring modified hexacyclic camptothecin analogues.
Journal of medicinal chemistry · 2001-05 · Kim DK, Ryu DH, Lee JY 외 7
- General pharmacology of the new antiviral agent SK 1899.
Arzneimittel-Forschung · 2000-04 · Ryu KH, Rhee HI, Jung I 외 13
- Synthesis and evaluation of 2-amino-9-(3-acyloxymethyl-4-alkoxycarbonyloxybut-1-yl)purines and 2-amino-9-(3-alkoxycarbonyloxymethyl-4-alkoxycarbonyloxybut-1- yl)purines as potential prodrugs of penciclovir.
Bioorganic & medicinal chemistry · 1999-08 · Kim DK, Lee N, Ryu DH 외 9
- Synthesis and evaluation of 2-amino-6-fluoro-9-(4-hydroxy-3-hydroxymethylbut-1-yl)purine mono- and diesters as potential prodrugs of penciclovir.
Bioorganic & medicinal chemistry · 1999-03 · Kim DK, Lee N, Kim HT 외 2
- Synthesis and evaluation of amino acid esters of 6-deoxypenciclovir as potential prodrugs of penciclovir.
Bioorganic & medicinal chemistry · 1999-02 · Kim DK, Lee N, Kim YW 외 4
- Synthesis and evaluation of 2-amino-9-(1, 3-dihydroxy-2-propoxymethyl)- 6-fluoropurine mono- and diesters as potential prodrugs of ganciclovir.
Journal of medicinal chemistry · 1999-01 · Kim DK, Chang K, Im GJ 외 3
- Synthesis and evaluation of 2-amino-6-fluoro-9-(2-hydroxyethoxymethyl)purine esters as potential prodrugs of acyclovir.
Bioorganic & medicinal chemistry · 1998-12 · Kim DK, Lee N, Im GJ 외 2
- Synthesis and evaluation of 2-amino-9-(3-hydroxymethyl-4-alkoxycarbonyloxybut-1-yl)purines as potential prodrugs of penciclovir.
Journal of medicinal chemistry · 1998-08 · Kim DK, Lee N, Kim YW 외 11
Patents
KIPRIS · applicant-matchedPublished · 2026-05 · Application 1020260094794
Published · 2026-02 · Application 1020260035793
Published · 2026-01 · Application 1020260012250
Published · 2025-11 · Application 1020250169759
TW · Published · 2025-09 · Application 114137718
TW · Published · 2025-09 · Application 114135164
TW · Published · 2025-09 · Application 114134942
TW · Published · 2025-09 · Application 114134717
PCT · Published · 2025-09 · Application PCT/KR2025/014078
TW · Published · 2025-09 · Application 114134361
Show 635 more patents
Published · 2025-09 · Application 1020250127451
Published · 2025-09 · Application 1020250127450
Published · 2025-09 · Application 1020250126653
Published · 2025-09 · Application 1020250126138
Published · 2025-09 · Application 1020250125202
PCT · Published · 2025-09 · Application PCT/KR2025/013415
TW · Published · 2025-08 · Application 114132927
TW · Published · 2025-07 · Application 114126758
TW · Published · 2025-07 · Application 114126016
TW · Published · 2025-05 · Application 114117735
TW · Published · 2025-04 · Application 114114800
TW · Published · 2025-04 · Application 114113574
TW · Published · 2025-04 · Application 114112821
TW · Published · 2025-03 · Application 114112137
Published · 2025-03 · Application 1020250037139
Published · 2025-03 · Application 1020250037135
Published · 2025-03 · Application 1020250037138
Published · 2025-03 · Application 1020250037535
TW · Published · 2025-03 · Application 114110081
TW · Published · 2025-03 · Application 114110094
Published · 2025-03 · Application 1020250034788
Published · 2025-03 · Application 1020250027742
Published · 2025-02 · Application 1020250026581
Published · 2025-02 · Application 1020250026595
TW · Published · 2025-02 · Application 114107443
Published · 2025-01 · Application 1020250006052
Published · 2024-12 · Application 1020240192416
Published · 2024-12 · Application 1020240190221
Published · 2024-11 · Application 1020240171241
Published · 2024-11 · Application 1020240170215
Published · 2024-11 · Application 1020240167175
CN · Published · 2024-11 · Application 202480004861.9
CN · Published · 2024-11 · Application 202480004983.8
EP · Published · 2024-11 · Application 24875627.2
EP · Published · 2024-11 · Application 24875626.4
PCT · Published · 2024-11 · Application PCT/KR2024/018265
PCT · Published · 2024-11 · Application PCT/KR2024/018261
Published · 2024-10 · Application 1020240147308
Published · 2024-10 · Application 1020240144585
TW · Published · 2024-10 · Application 113138469
CN · Published · 2024-10 · Application 202480065362.0
Published · 2024-10 · Application 1020240134826
Published · 2024-10 · Application 1020240134903
TW · Published · 2024-09 · Application 113135725
Published · 2024-09 · Application 1020240127504
CN · Published · 2024-09 · Application 202480060751.4
Published · 2024-09 · Application 1020240125951
Published · 2024-09 · Application 1020240126197
Published · 2024-09 · Application 1020240126157
Published · 2024-09 · Application 1020240126165
Published · 2024-09 · Application 1020240125845
Published · 2024-09 · Application 1020240125888
Published · 2024-09 · Application 1020240123343
TW · Published · 2024-09 · Application 113133262
CN · Published · 2024-08 · Application 202480055077.0
TW · Published · 2024-08 · Application 113132927
CN · Published · 2024-08 · Application 202480070645.4
CN · Published · 2024-08 · Application 202480062000.6
TW · Published · 2024-08 · Application 113131810
Published · 2024-08 · Application 1020240113666
TW · Published · 2024-08 · Application 113131591
Published · 2024-08 · Application 1020240113064
CN · Published · 2024-08 · Application 202480066546.9
PCT · Published · 2024-08 · Application PCT/KR2024/012341
Published · 2024-08 · Application 1020240110859
Published · 2024-08 · Application 1020240109730
TW · Published · 2024-08 · Application 113130370
TW · Registered · 2024-07 · Application 113127504
Registered · 2024-07 · Application 1020240097346
CN · Published · 2024-07 · Application 202480002961.8
Published · 2024-07 · Application 1020240093957
Published · 2024-07 · Application 1020240093958
TW · Published · 2024-07 · Application 113126457
US · Registered · 2024-07 · Application 18771379
Published · 2024-07 · Application 1020240092588
Published · 2024-07 · Application 1020240092589
Published · 2024-07 · Application 1020240089092
Published · 2024-07 · Application 1020240089093
Rejected · 2024-06 · Application 1020240084831
Published · 2024-06 · Application 1020240078249
Published · 2024-06 · Application 1020240076641
Published · 2024-06 · Application 1020240076640
Registered · 2024-06 · Application 1020240073693
CN · Published · 2024-05 · Application 202480035437.0
CN · Published · 2024-05 · Application 202480035436.6
TW · Published · 2024-05 · Application 113120019
CN · Published · 2024-05 · Application 202480036792.X
TW · Published · 2024-05 · Application 113118951
CN · Published · 2024-05 · Application 202480024181.3
Published · 2024-04 · Application 1020240052965
Published · 2024-04 · Application 1020240048557
TW · Published · 2024-04 · Application 113113369
CN · Published · 2024-04 · Application 202480038903.0
CN · Published · 2024-03 · Application 202480024182.8
Published · 2024-03 · Application 1020240037280
TW · Published · 2024-03 · Application 113109749
CN · Published · 2024-03 · Application 202480001253.2
CN · Published · 2024-03 · Application 202480001448.7
Published · 2024-02 · Application 1020240029857
Published · 2024-02 · Application 1020240030147
Published · 2024-02 · Application 1020240018834
CN · Published · 2024-01 · Application 202480008624.X
Registered · 2024-01 · Application 1020240007471
Published · 2024-01 · Application 1020240007491
Registered · 2024-01 · Application 1020240005896
Published · 2024-01 · Application 1020240004968
Published · 2023-12 · Application 1020230197775
Published · 2023-11 · Application 1020230171567
Published · 2023-11 · Application 1020230150059
Rejected · 2023-10 · Application 1020230145116
Published · 2023-10 · Application 1020230135418
CN · Published · 2023-09 · Application 202380013480.2
TW · Published · 2023-09 · Application 112136260
Published · 2023-09 · Application 1020230126579
CN · Published · 2023-09 · Application 202380072899.5
- Subsidiary: EntisPOLYESTER RESIN COMPRISING RECYCLED MONOMERS AND POWDER COATING COMPOSITION COMPRISING THE SAME
US · Published · 2023-09 · Application 19120674
- Subsidiary: EntisPOLYESTER RESIN CONTAINING RECYCLED MONOMER AND POWDER COATING COMPOSITION CONTAINING SAME
EP · Published · 2023-09 · Application 23877527.4
- Subsidiary: EntisPOLYESTER RESIN CONTAINING RECYCLED MONOMER AND POWDER COATING COMPOSITION CONTAINING SAME
PCT · Published · 2023-09 · Application PCT/KR2023/014082
CN · Published · 2023-09 · Application 202380013964.7
Published · 2023-09 · Application 1020230116787
Published · 2023-09 · Application 1020230116192
Published · 2023-08 · Application 1020230115512
CN · Published · 2023-08 · Application 202380021423.9
CN · Published · 2023-08 · Application 202380021424.3
CN · Published · 2023-08 · Application 202380074640.4
Published · 2023-08 · Application 1020230111336
Published · 2023-08 · Application 1020230110791
Published · 2023-08 · Application 1020230110158
Published · 2023-08 · Application 1020230106479
Published · 2023-08 · Application 1020230106478
CN · Published · 2023-08 · Application 202380071673.3
CN · Published · 2023-08 · Application 202380060310.X
Published · 2023-07 · Application 1020230099574
Published · 2023-07 · Application 1020230099575
Registered · 2023-07 · Application 1020230099519
Registered · 2023-06 · Application 1020230083807
Registered · 2023-06 · Application 1020230083806
TW · Published · 2023-06 · Application 112122971
Registered · 2023-06 · Application 1020230077485
CN · Published · 2023-06 · Application 202380047446.7
TW · Published · 2023-06 · Application 112121700
CN · Published · 2023-06 · Application 202380010286.9
Published · 2023-06 · Application 1020230073024
Published · 2023-05 · Application 1020230070475
Published · 2023-05 · Application 1020230070474
Published · 2023-05 · Application 1020230070188
Registered · 2023-05 · Application 1020230066551
CN · Published · 2023-04 · Application 202380015959.X
Registered · 2023-04 · Application 1020230048462
Published · 2023-04 · Application 1020230047347
Published · 2023-04 · Application 1020230047057
CN · Published · 2023-03 · Application 202380019981.1
Published · 2023-03 · Application 1020230037371
Published · 2023-03 · Application 1020230033829
Published · 2023-02 · Application 1020230020346
Published · 2023-01 · Application 1020230011887
Published · 2023-01 · Application 1020230011888
Published · 2023-01 · Application 1020230009078
Registered · 2023-01 · Application 1020230002201
Registered · 2022-11 · Application 1020220164709
Registered · 2022-11 · Application 1020220161481
Registered · 2022-11 · Application 1020220161476
Published · 2022-11 · Application 1020220158778
CN · Published · 2022-11 · Application 202280073330.6
Published · 2022-11 · Application 1020220145878
Published · 2022-10 · Application 1020220138598
Published · 2022-10 · Application 1020220133309
Published · 2022-10 · Application 1020220132210
Registered · 2022-09 · Application 1020220125338
US · Registered · 2022-09 · Application 18707310
PCT · Published · 2022-09 · Application PCT/KR2022/013899
Published · 2022-09 · Application 1020220112190
TW · Registered · 2022-08 · Application 111130772
TW · Registered · 2022-08 · Application 111130771
Published · 2022-08 · Application 1020220102297
US · Registered · 2022-07 · Application 17861991
Registered · 2022-07 · Application 1020220085160
Published · 2022-06 · Application 1020220076777
TW · Registered · 2022-06 · Application 111120699
TW · Registered · 2022-06 · Application 111120698
TW · Registered · 2022-06 · Application 111120472
TW · Registered · 2022-06 · Application 111120471
Published · 2022-05 · Application 1020220056794
Registered · 2022-05 · Application 1020220055673
Withdrawn · 2022-04 · Application 1020220049462
Registered · 2022-04 · Application 1020220049113
Published · 2022-04 · Application 1020220042550
Registered · 2022-03 · Application 1020220033329
Published · 2022-03 · Application 1020220029483
Registered · 2022-02 · Application 1020220025351
Published · 2021-12 · Application 1020210185099
Published · 2021-12 · Application 1020210179931
Published · 2021-11 · Application 1020210163700
Registered · 2021-11 · Application 1020210163841
Registered · 2021-11 · Application 1020210163840
Published · 2021-11 · Application 1020210158357
Published · 2021-11 · Application 1020210155790
CN · Published · 2021-11 · Application 202180072152.0
CN · Published · 2021-11 · Application 202511682079.5
EP · Published · 2021-11 · Application 21892235.9
PCT · Published · 2021-11 · Application PCT/KR2021/015874
Published · 2021-11 · Application 1020210150087
Published · 2021-11 · Application 1020210149601
Published · 2021-10 · Application 1020210134220
TW · Registered · 2021-09 · Application 110136579
Published · 2021-09 · Application 1020210120424
Published · 2021-08 · Application 1020210110703
Published · 2021-08 · Application 1020210108050
Published · 2021-08 · Application 1020210108049
Registered · 2021-08 · Application 1020210108277
Registered · 2021-08 · Application 1020210108276
Registered · 2021-08 · Application 1020210108279
Registered · 2021-08 · Application 1020210108278
Published · 2021-07 · Application 1020210099148
Published · 2021-07 · Application 1020210091174
Registered · 2021-06 · Application 1020210085989
Registered · 2021-06 · Application 1020210084939
Registered · 2021-06 · Application 1020210079300
Registered · 2021-06 · Application 1020210072733
Registered · 2021-06 · Application 1020210072734
Published · 2021-05 · Application 1020210059158
Registered · 2021-05 · Application 1020210059573
Registered · 2021-04 · Application 1020210053953
TW · Registered · 2021-04 · Application 110114518
Registered · 2020-11 · Application 1020200154565
Registered · 2020-11 · Application 1020200150209
Rejected · 2020-11 · Application 1020200149754
Registered · 2020-11 · Application 1020200147591
Registered · 2020-11 · Application 1020200145155
Registered · 2020-10 · Application 1020200139421
TW · Published · 2020-07 · Application 109125232
Published · 2020-07 · Application 1020200092287
Published · 2020-06 · Application 1020200079641
US · Registered · 2020-06 · Application 16902468
Registered · 2020-05 · Application 1020200062919
CN · Published · 2020-03 · Application 202080038090.7
CN · Published · 2020-03 · Application 202510126279.6
Published · 2020-03 · Application 1020257038856
Rejected · 2020-03 · Application 1020237003013
Withdrawn · 2020-03 · Application 1020217034463
Rejected · 2020-01 · Application 1020200009788
Expired · 2019-12 · Application 1020190170654
Expired · 2019-12 · Application 1020190170655
Registered · 2019-11 · Application 1020190154464
Registered · 2019-11 · Application 1020190154463
US · Registered · 2019-10 · Application 17287707
EP · Published · 2019-10 · Application 19876622.2
PCT · Published · 2019-10 · Application PCT/KR2019/013227
Registered · 2019-10 · Application 1020190121670
Registered · 2019-10 · Application 1020190121447
Registered · 2019-09 · Application 1020190119676
US · Registered · 2019-09 · Application 17287710
EP · Registered · 2019-09 · Application 19876284.1
PCT · Published · 2019-09 · Application PCT/KR2019/012505
US · Registered · 2019-08 · Application 17271638
EP · Published · 2019-08 · Application 19853585.8
PCT · Published · 2019-08 · Application PCT/KR2019/011212
Registered · 2019-07 · Application 1020190086936
US · Registered · 2019-07 · Application 17422683
EP · Published · 2019-07 · Application 19909753.6
PCT · Published · 2019-07 · Application PCT/KR2019/008505
Registered · 2019-07 · Application 1020190082671
TW · Registered · 2019-07 · Application 114113472
CN · Published · 2019-07 · Application 201980088895.X
US · Registered · 2019-07 · Application 17422699
EP · Published · 2019-07 · Application 19910782.2
PCT · Published · 2019-07 · Application PCT/KR2019/008312
Registered · 2019-07 · Application 1020190080466
EP · Registered · 2019-07 · Application 19834720.5
PCT · Published · 2019-07 · Application PCT/KR2019/008053
Rejected · 2019-05 · Application 1020190064945
Withdrawn · 2019-05 · Application 1020190064844
Registered · 2019-05 · Application 1020190063736
Registered · 2019-05 · Application 1020190051631
Registered · 2019-05 · Application 1020190051630
Registered · 2019-02 · Application 1020190015698
US · Registered · 2019-01 · Application 16960615
EP · Published · 2019-01 · Application 19744450.8
PCT · Published · 2019-01 · Application PCT/KR2019/001039
Registered · 2019-01 · Application 1020190009485
Registered · 2019-01 · Application 1020190002465
Registered · 2018-11 · Application 1020180146783
Rejected · 2018-11 · Application 1020180146751
Rejected · 2018-11 · Application 1020180146756
Registered · 2018-11 · Application 1020180145775
Rejected · 2018-11 · Application 1020180138443
Rejected · 2018-11 · Application 1020180138444
Registered · 2018-11 · Application 1020180137661
US · Registered · 2018-11 · Application 16757570
EP · Registered · 2018-11 · Application 18877033.3
PCT · Published · 2018-11 · Application PCT/KR2018/013491
PCT · Published · 2018-11 · Application PCT/KR2018/013549
Registered · 2018-11 · Application 1020180135681
Rejected · 2018-10 · Application 1020180129077
Registered · 2018-10 · Application 1020180129022
Registered · 2018-10 · Application 1020180127643
Rejected · 2018-10 · Application 1020180125484
Registered · 2018-10 · Application 1020180122093
Rejected · 2018-10 · Application 1020180120750
Registered · 2018-10 · Application 1020180119266
Withdrawn · 2018-09 · Application 1020180115780
Registered · 2018-09 · Application 1020180113233
US · Registered · 2018-09 · Application 16640472
EP · Registered · 2018-09 · Application 18861783.1
PCT · Published · 2018-09 · Application PCT/KR2018/010427
Registered · 2018-08 · Application 1020180103849
Registered · 2018-08 · Application 1020180103855
Registered · 2018-08 · Application 1020180100605
PCT · Published · 2018-08 · Application PCT/KR2018/009819
PCT · Published · 2018-08 · Application PCT/KR2018/009820
Registered · 2018-08 · Application 1020180092512
Registered · 2018-07 · Application 1020180087434
Registered · 2018-07 · Application 1020180080989
EP · Registered · 2018-06 · Application 18825358.7
Registered · 2018-06 · Application 1020180075484
Rejected · 2018-06 · Application 1020180075870
Rejected · 2018-06 · Application 1020180076016
Withdrawn · 2018-06 · Application 1020180074853
Registered · 2018-06 · Application 1020180072380
Registered · 2018-06 · Application 1020180069381
Registered · 2018-05 · Application 1020180062952
Registered · 2018-05 · Application 1020180060813
Withdrawn · 2018-05 · Application 1020180058786
Registered · 2018-05 · Application 1020180056186
Withdrawn · 2018-05 · Application 1020180055816
PCT · Published · 2018-04 · Application PCT/KR2018/004206
US · Registered · 2018-04 · Application 15945092
Withdrawn · 2018-04 · Application 1020180039300
Registered · 2018-03 · Application 1020180025354
Registered · 2018-02 · Application 1020180015038
Registered · 2018-02 · Application 1020180014988
Withdrawn · 2018-01 · Application 1020180007512
Registered · 2018-01 · Application 1020180004978
Registered · 2017-12 · Application 1020170177509
Registered · 2017-12 · Application 1020170166961
Registered · 2017-11 · Application 1020170159210
Registered · 2017-11 · Application 1020170159164
Registered · 2017-11 · Application 1020170159170
Withdrawn · 2017-11 · Application 1020170157438
Registered · 2017-11 · Application 1020170154692
Withdrawn · 2017-11 · Application 1020170152431
Registered · 2017-09 · Application 1020170127721
Registered · 2017-09 · Application 1020170128260
Expired · 2017-09 · Application 1020170122818
Registered · 2017-09 · Application 1020170121962
Registered · 2017-09 · Application 1020170121963
Expired · 2017-09 · Application 1020170118025
Withdrawn · 2017-08 · Application 1020170106811
Registered · 2017-08 · Application 1020170105637
Registered · 2017-08 · Application 1020170105619
Withdrawn · 2017-08 · Application 1020170105568
US · Registered · 2017-07 · Application 15663092
Withdrawn · 2017-07 · Application 1020170089546
Withdrawn · 2017-07 · Application 1020170085780
Withdrawn · 2017-06 · Application 1020170083426
Registered · 2017-06 · Application 1020170080531
Registered · 2017-06 · Application 1020170070919
Withdrawn · 2017-05 · Application 1020170065472
Registered · 2017-05 · Application 1020170061436
Expired · 2017-05 · Application 1020170056388
Registered · 2017-04 · Application 1020170053467
Rejected · 2017-04 · Application 1020170052693
Expired · 2017-04 · Application 1020170051803
Registered · 2017-04 · Application 1020170051261
Abandoned · 2017-04 · Application 1020170049656
Registered · 2017-04 · Application 1020170049304
US · Published · 2017-04 · Application 16475461
EP · Registered · 2017-04 · Application 17891964.3
EP · Registered · 2017-04 · Application 17806885.4
Rejected · 2017-03 · Application 1020170035447
Expired · 2017-03 · Application 1020170034441
US · Registered · 2017-02 · Application 15445080
Rejected · 2017-02 · Application 1020170026720
EP · Published · 2017-01 · Application 17770475.6
Rejected · 2017-01 · Application 1020170008239
Registered · 2017-01 · Application 1020170006313
US · Registered · 2017-01 · Application 16063387
EP · Registered · 2017-01 · Application 17747627.2
PCT · Published · 2017-01 · Application PCT/KR2017/000135
Withdrawn · 2017-01 · Application 1020170000805
Withdrawn · 2016-12 · Application 1020160175615
Withdrawn · 2016-12 · Application 1020160169259
Registered · 2016-12 · Application 1020160168859
Withdrawn · 2016-12 · Application 1020160168861
Registered · 2016-11 · Application 1020160157612
Registered · 2016-11 · Application 1020160157613
Withdrawn · 2016-11 · Application 1020160156441
Withdrawn · 2016-11 · Application 1020160156405
Withdrawn · 2016-10 · Application 1020160132426
Withdrawn · 2016-10 · Application 1020160132419
Registered · 2016-09 · Application 1020160119930
Withdrawn · 2016-09 · Application 1020160115537
Registered · 2016-09 · Application 1020160115089
US · Published · 2016-08 · Application 15754702
EP · Published · 2016-08 · Application 16839664.6
Withdrawn · 2016-08 · Application 1020160109497
Withdrawn · 2016-08 · Application 1020160109486
Withdrawn · 2016-08 · Application 1020160107956
Rejected · 2016-07 · Application 1020160087327
Withdrawn · 2016-04 · Application 1020160046713
Registered · 2016-04 · Application 1020160043002
Registered · 2016-04 · Application 1020160042845
Registered · 2016-04 · Application 1020160042407
Registered · 2016-03 · Application 1020160035223
Registered · 2016-03 · Application 1020160027085
Registered · 2016-03 · Application 1020160027136
Registered · 2016-03 · Application 1020160026836
PCT · Published · 2016-02 · Application PCT/KR2016/001898
Registered · 2016-02 · Application 1020160014425
Withdrawn · 2016-02 · Application 1020160014461
US · Registered · 2016-01 · Application 15540052
EP · Registered · 2016-01 · Application 16740345.0
PCT · Published · 2016-01 · Application PCT/KR2016/000279
Registered · 2016-01 · Application 1020160002851
Withdrawn · 2015-12 · Application 1020150186698
Withdrawn · 2015-12 · Application 1020150186680
Withdrawn · 2015-12 · Application 1020150171529
Withdrawn · 2015-11 · Application 1020150165538
Withdrawn · 2015-11 · Application 1020150165526
Withdrawn · 2015-11 · Application 1020150165500
Rejected · 2015-11 · Application 1020150164714
Withdrawn · 2015-11 · Application 1020150161426
Expired · 2015-11 · Application 1020150161428
Rejected · 2015-11 · Application 1020150158165
US · Registered · 2015-11 · Application 14930573
Registered · 2015-11 · Application 1020150153044
EP · Registered · 2015-10 · Application 15855249.7
US · Published · 2015-10 · Application 14924373
Withdrawn · 2015-10 · Application 1020150149758
Registered · 2015-10 · Application 1020150148310
Withdrawn · 2015-10 · Application 1020150148280
US · Published · 2015-10 · Application 15518563
EP · Published · 2015-10 · Application 15850989.3
Withdrawn · 2015-10 · Application 1020150139029
Withdrawn · 2015-10 · Application 1020150138402
EP · Registered · 2015-09 · Application 15187105.0
Withdrawn · 2015-09 · Application 1020150129207
Expired · 2015-08 · Application 1020150120475
Rejected · 2015-08 · Application 1020150120476
Withdrawn · 2015-08 · Application 1020150114934
Withdrawn · 2015-07 · Application 1020150107269
Expired · 2015-07 · Application 1020150101753
Withdrawn · 2015-07 · Application 1020150099151
Withdrawn · 2015-06 · Application 1020150093024
Rejected · 2015-06 · Application 1020150085320
Registered · 2015-05 · Application 1020150067402
Expired · 2015-05 · Application 1020150067442
Registered · 2015-04 · Application 1020150057180
Rejected · 2015-04 · Application 1020150046096
Withdrawn · 2015-03 · Application 1020150037479
Registered · 2015-02 · Application 1020150019748
US · Registered · 2015-02 · Application 15116982
EP · Registered · 2015-02 · Application 15746056.9
Withdrawn · 2015-01 · Application 1020150011555
Registered · 2015-01 · Application 1020150010826
Rejected · 2015-01 · Application 1020150003643
Withdrawn · 2015-01 · Application 1020150002874
Registered · 2015-01 · Application 1020150001240
Withdrawn · 2015-01 · Application 1020150001245
Rejected · 2015-01 · Application 1020150000760
Expired · 2014-12 · Application 1020140190451
Registered · 2014-12 · Application 1020140188718
Rejected · 2014-12 · Application 1020140184899
Expired · 2014-12 · Application 1020140179473
PCT · Published · 2014-12 · Application PCT/KR2014/012195
Expired · 2014-12 · Application 1020140172447
Expired · 2014-11 · Application 1020140167791
Withdrawn · 2014-11 · Application 1020140163487
Withdrawn · 2014-11 · Application 1020140163459
Expired · 2014-11 · Application 1020140162798
Registered · 2014-11 · Application 1020140161080
Expired · 2014-11 · Application 1020140158963
Expired · 2014-11 · Application 1020140156340
Registered · 2014-10 · Application 1020140150404
Registered · 2014-10 · Application 1020140150405
Registered · 2014-10 · Application 1020140150407
Registered · 2014-10 · Application 1020140150402
Registered · 2014-10 · Application 1020140145512
Rejected · 2014-10 · Application 1020140143329
Expired · 2014-10 · Application 1020140139909
Registered · 2014-10 · Application 1020140132199
Registered · 2014-10 · Application 1020140132266
Registered · 2014-09 · Application 1020140123892
Withdrawn · 2014-09 · Application 1020140119125
US · Registered · 2014-09 · Application 14916446
EP · Registered · 2014-09 · Application 14842517.6
Expired · 2014-09 · Application 1020140117898
Expired · 2014-09 · Application 1020140117897
Registered · 2014-08 · Application 1020140111841
Registered · 2014-08 · Application 1020140111843
Registered · 2014-08 · Application 1020140107738
- Subsidiary: EntisGREENHOUSE HEATING DEVICE USING FLUID HEAT GENERATOR
PCT · Published · 2014-08 · Application PCT/KR2014/007163
US · Registered · 2014-07 · Application 14903401
EP · Registered · 2014-07 · Application 14829080.2
US · Registered · 2014-06 · Application 14901281
US · Published · 2014-06 · Application 14901263
Registered · 2014-06 · Application 1020140072811
Registered · 2014-06 · Application 1020140072810
Expired · 2014-06 · Application 1020140072807
US · Registered · 2014-06 · Application 14897774
US · Registered · 2014-06 · Application 14897752
EP · Published · 2014-06 · Application 14810636.2
EP · Published · 2014-06 · Application 14811078.6
Registered · 2014-06 · Application 1020140068622
Registered · 2014-06 · Application 1020140068620
Withdrawn · 2014-06 · Application 1020140066888
Registered · 2014-05 · Application 1020140061193
Withdrawn · 2014-05 · Application 1020140060059
Withdrawn · 2014-05 · Application 1020140059129
Rejected · 2014-05 · Application 1020140059083
Registered · 2014-04 · Application 1020140043788
US · Registered · 2014-02 · Application 14179909
Registered · 2014-02 · Application 1020140014377
US · Registered · 2014-02 · Application 14765942
EP · Registered · 2014-02 · Application 14749357.1
Registered · 2014-01 · Application 1020140001485
Rejected · 2014-01 · Application 1020140001193
Withdrawn · 2013-12 · Application 1020130160002
Withdrawn · 2013-12 · Application 1020130160292
Rejected · 2013-12 · Application 1020130158231
JP · Published · 2013-12 · Application 27547844
CN · Published · 2013-12 · Application 201811143297.1
CN · Published · 2013-12 · Application 201380063366
US · Registered · 2013-12 · Application 14649467
EP · Registered · 2013-12 · Application 13860159.6
EP · Published · 2013-12 · Application 26186797.2
EP · Published · 2013-12 · Application 21209760.4
Registered · 2013-12 · Application 1020130150144
Registered · 2013-11 · Application 1020130142820
Rejected · 2013-10 · Application 1020130128438
Registered · 2013-10 · Application 1020130128001
Withdrawn · 2013-10 · Application 1020130126128
Rejected · 2013-10 · Application 1020130120615
Rejected · 2013-10 · Application 1020130118083
Registered · 2013-09 · Application 1020130113181
Withdrawn · 2013-09 · Application 1020130112615
Expired · 2013-09 · Application 1020130112008
Rejected · 2013-09 · Application 1020130111550
Abandoned · 2013-08 · Application 1020130104023
Expired · 2013-08 · Application 1020130102575
Withdrawn · 2013-08 · Application 1020130100362
Abandoned · 2013-08 · Application 1020130099148
Rejected · 2013-08 · Application 1020130096172
Rejected · 2013-08 · Application 1020130093262
Registered · 2013-07 · Application 1020130087638
Withdrawn · 2013-07 · Application 1020130080451
Abandoned · 2013-07 · Application 1020130079852
Withdrawn · 2013-07 · Application 1020130079838
Registered · 2013-06 · Application 1020130075863
Expired · 2013-06 · Application 1020130075872
Expired · 2013-06 · Application 1020130075871
Registered · 2013-06 · Application 1020130071823
Withdrawn · 2013-06 · Application 1020130070867
JP · Published · 2013-06 · Application 27518332
Withdrawn · 2013-06 · Application 1020130070404
Abandoned · 2013-06 · Application 1020130067871
Expired · 2013-06 · Application 1020130066772
Expired · 2013-06 · Application 1020130066771
Registered · 2013-05 · Application 1020130060455
US · Registered · 2013-05 · Application 14405189
US · Registered · 2013-05 · Application 14405203
US · Registered · 2013-05 · Application 14403639
EP · Registered · 2013-05 · Application 13800650.7
EP · Registered · 2013-05 · Application 13799976.9
EP · Registered · 2013-05 · Application 13793953.4
Registered · 2013-05 · Application 1020130049543
Registered · 2013-04 · Application 1020147033613
Withdrawn · 2013-04 · Application 1020130041060
Registered · 2013-04 · Application 1020130037047
Registered · 2013-04 · Application 1020130037073
Withdrawn · 2013-03 · Application 1020130034508
Registered · 2013-03 · Application 1020130029039
Registered · 2013-03 · Application 1020130027857
EP · Registered · 2013-02 · Application 13752441.9
Expired · 2013-02 · Application 1020130013450
Registered · 2013-01 · Application 1020130004456
Expired · 2012-12 · Application 1020120153231
Abandoned · 2012-12 · Application 1020120152980
Expired · 2012-12 · Application 1020120147112
Registered · 2012-12 · Application 1020120140370
Expired · 2012-11 · Application 1020120132280
Rejected · 2012-10 · Application 1020120120864
Expired · 2012-10 · Application 1020120120664
Expired · 2012-09 · Application 1020120108183
Expired · 2012-09 · Application 1020120106005
Rejected · 2012-09 · Application 1020120104727
Expired · 2012-09 · Application 1020120103990
Expired · 2012-08 · Application 1020120095101
Expired · 2012-07 · Application 1020120072865
Registered · 2012-07 · Application 1020120072278
Abandoned · 2012-06 · Application 1020120069451
Rejected · 2012-06 · Application 1020120063364
Rejected · 2012-06 · Application 1020120063365
Expired · 2012-06 · Application 1020120062213
Registered · 2012-06 · Application 1020120060452
Registered · 2012-06 · Application 1020120060453
Rejected · 2012-06 · Application 1020120060463
Registered · 2012-05 · Application 1020120056282
Rejected · 2012-05 · Application 1020120055202
Rejected · 2012-05 · Application 1020120055055
Rejected · 2012-05 · Application 1020120053447
EP · Registered · 2012-04 · Application 12768544.4
Registered · 2012-03 · Application 1020120023940
Rejected · 2012-02 · Application 1020120019335
US · Published · 2011-10 · Application 13881583
EP · Registered · 2011-10 · Application 11836658.2
PCT · Published · 2011-10 · Application PCT/KR2011/007795
Rejected · 2011-04 · Application 1020110039316
PCT · Published · 2011-01 · Application PCT/KR2011/000064
Registered · 2010-12 · Application 1020100130224
PCT · Published · 2010-11 · Application PCT/KR2010/008449
PCT · Published · 2009-11 · Application PCT/KR2009/006381
PCT · Published · 2009-10 · Application PCT/KR2009/005907
PCT · Published · 2008-08 · Application PCT/KR2008/004728
PCT · Published · 2008-07 · Application PCT/KR2008/003940
PCT · Published · 2008-01 · Application PCT/KR2008/000051
PCT · Published · 2008-01 · Application PCT/KR2008/000049
PCT · Published · 2007-11 · Application PCT/KR2007/005923
PCT · Published · 2007-09 · Application PCT/KR2007/004367
PCT · Published · 2007-09 · Application PCT/KR2007/004366
PCT · Published · 2007-07 · Application PCT/KR2007/003473
US · Published · 2007-07 · Application 12307144
EP · Registered · 2007-07 · Application 07768581.6
PCT · Published · 2007-07 · Application PCT/KR2007/003213
PCT · Published · 2006-08 · Application PCT/KR2006/003332
PCT · Published · 2005-12 · Application PCT/KR2005/004664
PCT · Published · 2005-02 · Application PCT/KR2005/000323
PCT · Published · 2004-11 · Application PCT/KR2004/002836
PCT · Published · 2003-02 · Application PCT/KR2003/000380
EP · Registered · 2002-11 · Application 02788984.9
PCT · Published · 2002-11 · Application PCT/KR2002/002180
PCT · Published · 2002-04 · Application PCT/KR2002/000631
PCT · Published · 2001-11 · Application PCT/KR2001/002038
PCT · Published · 2000-11 · Application PCT/KR2000/001280
PCT · Published · 1999-11 · Application PCT/KR1999/000687
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive4
- OpenAIOAI-SearchBot215
- GoogleGoogleOther32
- PerplexityPerplexityBot6
- AnthropicClaudeBot2
Measured since Aug 25, 2026 · 4 AI engines · last read Oct 8, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for SK Chemicals Co., Ltd. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies approved for the same productsBiotech & Drug Discovery
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.
Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.
KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
Medipost, founded in 2000 and KOSDAQ-listed in 2005, specializes in cord blood banking and stem cell therapeutics.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition